195 related articles for article (PubMed ID: 29909874)
21. Anticipated changes in reimbursements for US outpatient emergency department encounters after health reform.
Galarraga JE; Pines JM
Ann Emerg Med; 2014 Apr; 63(4):412-7.e2. PubMed ID: 24176577
[TBL] [Abstract][Full Text] [Related]
22. Real-world economic burden of hepatitis C and impact of direct-acting antivirals in France: A nationwide claims data analysis.
Lam L; Carrieri P; Hejblum G; Bellet J; Bourlière M; Carrat F
Liver Int; 2024 May; 44(5):1233-1242. PubMed ID: 38375961
[TBL] [Abstract][Full Text] [Related]
23. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
Durham DP; Skrip LA; Bruce RD; Vilarinho S; Elbasha EH; Galvani AP; Townsend JP
Clin Infect Dis; 2016 Feb; 62(3):298-304. PubMed ID: 26628566
[TBL] [Abstract][Full Text] [Related]
24. Role Of Generics In Treatment Of Hepatitis C Infection.
Umar M; Akhter TS; Akbar I; Nisar G; Osama M; Akhter TS
J Ayub Med Coll Abbottabad; 2016; 28(4 Suppl 1):S890-S894. PubMed ID: 28782339
[TBL] [Abstract][Full Text] [Related]
25. Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics.
Liao JM; Fischer MA
Am J Public Health; 2017 Jun; 107(6):893-899. PubMed ID: 28426313
[TBL] [Abstract][Full Text] [Related]
26. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
[TBL] [Abstract][Full Text] [Related]
27. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.
Wong RJ; Jain MK; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Thamer M
Am J Gastroenterol; 2018 Sep; 113(9):1329-1338. PubMed ID: 29523864
[TBL] [Abstract][Full Text] [Related]
28. Differences in the cost of antidepressants across state Medicaid programs.
Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
[TBL] [Abstract][Full Text] [Related]
29. Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.
Lo Re V; Gowda C; Urick PN; Halladay JT; Binkley A; Carbonari DM; Battista K; Peleckis C; Gilmore J; Roy JA; Doshi JA; Reese PP; Reddy KR; Kostman JR
Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1035-43. PubMed ID: 27062903
[TBL] [Abstract][Full Text] [Related]
30. Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014.
Luo J; Avorn J; Kesselheim AS
JAMA Intern Med; 2015 Oct; 175(10):1681-6. PubMed ID: 26301721
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
[TBL] [Abstract][Full Text] [Related]
32. Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United States.
Auty SG; Griffith KN; Shafer PR; Gee RE; Conti RM
J Health Polit Policy Law; 2022 Dec; 47(6):691-708. PubMed ID: 35867531
[TBL] [Abstract][Full Text] [Related]
33. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong.
Li X; Chan NS; Tam AW; Hung IFN; Chan EW
Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1801-1809. PubMed ID: 28516201
[TBL] [Abstract][Full Text] [Related]
34. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
[TBL] [Abstract][Full Text] [Related]
35. The Burden of Chronic Hepatitis C in China From 2004 to 2050: An Individual-Based Modeling Study.
Wu J; Zhou Y; Fu X; Deng M; Zheng Y; Tian G; Li Y; Wang C; Ding C; Ruan B; Yang S; Li L
Hepatology; 2019 Apr; 69(4):1442-1452. PubMed ID: 30561833
[TBL] [Abstract][Full Text] [Related]
36. Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist.
Nephew LD; Wang Y; Mohamed K; Nichols D; Rawl SM; Orman E; Desai AP; Patidar KR; Ghabril M; Chalasani N; Kasting ML
J Viral Hepat; 2022 May; 29(5):366-374. PubMed ID: 35254695
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a specialty hepatitis C virus telephone pharmacy service.
Sabourin AA; Fisher-Grant KK; Saulles AR; Mohammad RA
Am J Health Syst Pharm; 2021 May; 78(Supplement_2):S38-S45. PubMed ID: 33684928
[TBL] [Abstract][Full Text] [Related]
38. Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications.
Auty SG; Shafer PR; Griffith KN
JAMA Health Forum; 2021 Aug; 2(8):e212291. PubMed ID: 35977192
[TBL] [Abstract][Full Text] [Related]
39. State Coverage and Reimbursement of Antiobesity Medications in Medicaid.
Liu BY; Rome BN
JAMA; 2024 Apr; 331(14):1230-1232. PubMed ID: 38483403
[TBL] [Abstract][Full Text] [Related]
40. Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.
Canary LA; Klevens RM; Holmberg SD
Ann Intern Med; 2015 Aug; 163(3):226-8. PubMed ID: 26121095
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
